Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   19/12/2025
4,900 USD (+3,59%)
(+3,59%)   19/12/2025
Grafiek Alvotech Grafiek Alvotech

Alvotech in het nieuws

19 december 2025 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

17 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

17 december 2025 · Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering · Persbericht

16 december 2025 · Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance · Persbericht

11 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

3 december 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

24 november 2025 · Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area · Persbericht

20 november 2025 · Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) · Persbericht

13 november 2025 · Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman · Persbericht

12 november 2025 · Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update · Persbericht

Mijn selecties